No Data
No Data
China Biopharmaceutical (01177) will pay a final dividend of HK$0.03 per share on July 5
China Biopharmaceutical (01177) announced that the company will pay a final dividend of 0 per share on July 5, 2024...
China Biopharmaceutical (01177) announced annual results. Profit attributable to shareholders of 2,332 billion yuan decreased by 8.32% year-on-year to increase investment in R&D
According to the Zhitong Finance App, China Biopharmaceutical (01177) announced results for the year ended December 31, 2023. The group achieved continuous operating revenue of 26.199 billion yuan (RMB, same below) during the period, an increase of 0.67%; profit attributable to shareholders of 2,332 billion yuan, a year-on-year decrease of 8.32%; basic profit per share of 12.59 points; and plans to distribute a final dividend of HK3 cents per share. The announcement stated that the Group has always attached great importance to R&D, combining R&D concepts of independent innovation, joint development and imitation development, continuously improving the level and speed of R&D, and regards it as the foundation for sustainable development
SINO BIOPHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Sino Biopharmaceutical's Diagnostic Agent Injection Gets Marketing Nod in China
Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration gave the marketing approval to its Iopromide Injection, according to a Hong Kong bourse filing on Monday. The in
China Biopharmaceutical (01177.HK): Medical imaging product “iopromide injection” approved for listing
On March 25, Ge Longhui | China Biopharmaceutical (01177.HK) announced that the medical imaging product iopromide injection (trade name: polyiodine) developed by the Group has obtained marketing approval from China's State Drug Administration. For diagnostic use, it can be used for intravascular and intra-body imaging. According to the disclosure, iopromide is a triiodized non-ionic water-soluble X-ray contrast agent with high iodine content and good contrast effect. It is mostly used for computer X-ray tomography (CT) enhancement, arteriography and venography, endoscopic retrograde cholangiopancreatography (ERCP), joint cavity imaging, and other body cavity tests
Sino Biopharmaceutical's Developing Two Drugs for MASH
Sino Biopharmaceutical (HKG:1177) said two drugs, lanifibranor (pan-PPAR agonist) and TQA2225, jointly developed by the group, are undergoing Phase III and Phase II clinical trials, respectively in Ch
No Data